Portola's Rocky Commercial Transition On Show In Q2, With No CEO
Company reported only $33,000 in sales for late anticoagulant market entrant Bevyxxa and $2.2m for the antidote Andexxa, leaving a lot of challenges ahead after the retirement of CEO Bill Lis, effective Aug. 1.
You may also be interested in...
Portola touts exec's commercial management experience with Genentech success stories Avastin and Tarceva.
Keeping Track: J&J Esketamine, Sanofi Caplacizumab Lead Off September Submissions; US FDA Says No To Nucala
The latest drug development news and highlights from our US FDA Performance Tracker.
The European Medicines Agency this month recommended EU marketing approval for a raft of products, including what could become Europe's first two biosimilar versions of the blockbuster drug, Neulasta.